Fulvestrant formulations and methods of their use
The present disclosure provides methods of treating breast cancer including administering aqueous suspensions com-prising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(1 0) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.
1. An aqueous suspension comprising:
solubilized fulvestrant;
non-solubilized fulvestrant particles having one or more of:
a laser diffraction diameter ( 10 ) LD Dv ( 10 ) between about 1.5 microns and about 2.1 microns,
an LD Dv ( 50 ) between about 5.5 microns and about 9.0 microns, and
an LD Dv ( 90 ) between about 15 microns and about 35 microns;
a surfactant;
a polyvinylpyrrolidone; and
a sugar alcohol; and
a water-soluble excipient that is:
an aryl-C 1-6 alk-OH,
a C 1-6 alkyl-OH,
a buffering salt,
a polysorbate,
a polyalkylene glycol,
a C 1-12 alkylene glycol,
a phosphatidylcholine,
or a combination thereof.
2. The suspension of claim 1 , wherein the aqueous suspension comprises between about 0.1% and about 5% (w/w), between about 0.5% and about 5% (w/w), between about 0.5% and about 2.5% (w/w), between about 0.9% and about 1.5% (w/w), about 4% (w/w), or about 1% (w/w) of the aryl-C 1-6 alk-OH.
3. The suspension of claim 1 , wherein the aryl-C 1-6 alk-OH is benzyl alcohol.
4. The suspension of claim 1 , wherein the aqueous suspension comprises between about 1% and about 10% (w/w), between about 5% and about 10% (w/w), between about 2% and about 4% (w/w), about 2% (w/w), about 4% (w/w), about 5% (w/w), or about 8% (w/w) of the C 1-6 alkyl-OH.
5. The suspension of claim 1 , wherein the C 1-6 alkyl-OH is ethanol.
6. The suspension of claim 1 , wherein the buffering salt is NaH 2 PO 4 , K 2 HPO 4 , KH 2 PO 4 , citric acid or a pharmaceutically acceptable salt thereof, tromethane or a pharmaceutically acceptable salt thereof, or a mixture thereof.
7. The suspension of claim 1 , wherein the aqueous suspension comprises between about 0.1% to about 2% (w/w), between about 0.25% and about 1.80% (w/w), or about 0.75% (w/w), of the polysorbate.
8. The suspension of claim 1 , wherein the polysorbate is polysorbate 20 , polysorbate 60 , polysorbate 80 , or a combination thereof.
9. The suspension of claim 1 , wherein the aqueous suspension comprises between about 1% and about 10% (w/w), between about 0.5% and about 8% (w/w), or about 5% (w/w) of the polyalkylene glycol.
10. The suspension of claim 1 , wherein the polyalkylene glycol is a polyethylene glycol.
11. The suspension of claim 1 , wherein the aqueous suspension comprises between about 0.1% and about 5% (w/w), between about 0.5% and about 4% (w/w), or about 2.5% (w/w) of the C 1-12 alkylene glycol.
12. The suspension of claim 1 , wherein the C 1-12 alkylene glycol is propylene glycol.
13. The suspension of claim 1 , wherein the aqueous suspension comprises between about 0.1% and about 5% (w/w), between about 0.1% and about 2% (w/w), or about 0.3% (w/w) of the phosphatidylcholine.
14. The suspension of claim 1 , wherein the phosphatidylcholine is lecithin.
15. The suspension of claim 1 , wherein the water soluble excipient is an aryl-C 1-6 alk-OH, a C 1-6 alkyl-OH, a polysorbate, or a buffering salt, or a combination thereof.
16. The suspension of claim 1 , wherein the aqueous suspension has a pH of between about 6.0 and about 8.0, about 7, or about 7.5.
17. The suspension of claim 1 , wherein the sugar alcohol is mannitol, xylitol, maltitol, lactitol, maltotriitol, sorbitol, glycerol, or a mixture thereof.
18. The method of claim 1 , wherein the total amount of fulvestrant from solubilized fulvestrant and non-solubilized fulvestrant particles in the aqueous suspension is between about 80 mg/mL and about 170 mg/mL or about 100 mg/mL.